Medication Use and Treatment Indications in Huntington's Disease; Analyses from a Large Cohort

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Huntington's Disease (HD) is a rare neurodegenerative disorder requiring careful medication management.
• Current understanding of actual medication use patterns in HD is limited.

Purpose of the Study:

• To provide a comprehensive overview of medication use in HD.
• To analyze medication indications across different HD disease stages.
• To explore variations in medication use based on sex and geographic region.

Main Methods:

• Utilized data from the ENROLL-HD observational study, the largest of its kind.
• Developed medication and indication classes to identify trends in premanifest, manifest, and control subjects.
• Examined medication use in adult, childhood- and adolescent-onset HD, considering disease stage, phenoconversion, sex, and region.

Main Results:

• 84.6% of 8546 manifest HD patients used medication, with average prescriptions increasing from 2.5 to 5.2 from premanifest to end-stage disease.
• Most common medications included antipsychotics (29.2%), SSRIs (27.5%), and painkillers (21.8%).
• Medication use rose post-phenoconversion, with notable differences observed between sexes and regions (Europe vs. Northern America). Childhood-onset HD showed distinct patterns, including no painkiller use and increased medication for aggression.

Conclusions:

• Medication use in Huntington's Disease escalates with disease progression.
• Prescribed medications differ based on disease stage, patient sex, and geographic location.
• Understanding these medication trends is crucial for tailoring personalized management strategies for HD patients.